Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action antagonists, enhancers |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Phase 2 | United States | 13 Feb 2009 | |
| Obesity, Morbid | Phase 1 | United States | 01 Jan 2007 | |
| Nervous System Diseases | Preclinical | United States | 01 Apr 1995 |
Early Phase 1 | 61 | dbulyjnbzb = ixtswbeeel plmiqqnzyk (alcsmgqabe, rifgbgcjfh - prpcltwyxb) View more | - | 03 May 2023 | |||
Phase 1 | 7 | ylueigcggg(giexbqzpdi) = jvipifrlgl gxkciqrgsl (hngigowdws, 2.74) View more | - | 17 Mar 2017 |





